drugset
drugset / Trial / NCT02432326

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

NCT02432326 ↗

Phase 1 Completed 147 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, multi-center, phase 1 study of BBI608 and BBI503 administered orally in combination to patients with advanced solid tumors. The primary goal is to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination regimen.

Timeline

Start
2015-04
Primary completion
2019-12
Completion
2020-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AMCASERTIB Small molecule 100 mg Oral
Subject AMCASERTIB Small molecule 200 mg Oral
Subject Napabucasin Small molecule 80 mg Oral
Subject Napabucasin Small molecule 160 mg Oral
Subject Napabucasin Small molecule 240 mg Oral
Subject Napabucasin Small molecule 480 mg Oral

Indications

cancer